Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Annals of Hematology
|
December 19, 2014
WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients
Liyuan Ma, Siguo Hao, Colin Diong, et al.
Blood
|
February 11, 2026
Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming
Yandan Chen, Jinghao Shen, Zaisheng Lin, et al.
Bone Marrow Transplantation
|
December 20, 2024
Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai
Fangfang Yu, Jiahua Niu, Jianmin Yang, et al.
The Lancet. Haematology
|
June 30, 2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
Yuqin Song, Yanyan Liu, Zhi-Ming Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2024
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Yuqin Song, Zhengming Jin, Zhi-Ming Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
Huiqiang Huang, Rong Tao, Siguo Hao, et al.
Bone Marrow Transplantation
|
February 27, 2019
Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation
Baolin Tang, Xiaoyu Zhu, Changcheng Zheng, et al.
Experimental Hematology & Oncology
|
October 1, 2025
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Wenming Chen, Chengcheng Fu, Baijun Fang, et al.
Journal of Hematology & Oncology
|
May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao, Jieping Wei, Guoqing Wei, et al.
Blood Advances
|
June 5, 2023
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Emmanuel Bachy, Kerry J Savage, Huiqiang Huang, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Annals of Hematology
|
December 19, 2014
WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients
Liyuan Ma, Siguo Hao, Colin Diong, et al.
Blood
|
February 11, 2026
Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming
Yandan Chen, Jinghao Shen, Zaisheng Lin, et al.
Bone Marrow Transplantation
|
December 20, 2024
Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai
Fangfang Yu, Jiahua Niu, Jianmin Yang, et al.
The Lancet. Haematology
|
June 30, 2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
Yuqin Song, Yanyan Liu, Zhi-Ming Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2024
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Yuqin Song, Zhengming Jin, Zhi-Ming Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
Huiqiang Huang, Rong Tao, Siguo Hao, et al.
Bone Marrow Transplantation
|
February 27, 2019
Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation
Baolin Tang, Xiaoyu Zhu, Changcheng Zheng, et al.
Experimental Hematology & Oncology
|
October 1, 2025
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Wenming Chen, Chengcheng Fu, Baijun Fang, et al.
Journal of Hematology & Oncology
|
May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao, Jieping Wei, Guoqing Wei, et al.
Blood Advances
|
June 5, 2023
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Emmanuel Bachy, Kerry J Savage, Huiqiang Huang, et al.
Page
of 7